SCHEMBL12417527

SCHEMBL12417527

CCC(=O)NCCCCC(NC(=O)CC)C(=O)NC(CS)C(N)=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
SIRT5 Q9NXA8 2/20 0.45
TLR2 O60603 1/20 0.44
NPY4R P50391 5/20 0.43
NPY1R P25929 5/20 0.43
NPY2R P49146 4/20 0.43
NPY5R Q15761 4/20 0.43
SIRT6 Q8N6T7 1/20 0.40
SIRT1 Q96EB6 1/20 0.40
ALB P02768 1/20 0.38
NMT2 O60551 1/20 0.38
NMT1 P30419 1/20 0.38
FNTA P49354 2/20 0.37
FNTB P49356 2/20 0.37
PGGT1B P53609 1/20 0.37
ROCK2 O75116 2/20 0.37
PRKACA P17612 1/20 0.37
AKT3 Q9Y243 1/20 0.37
PTPN1 P18031 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13372149 0.92 SIRT5 (0.54) MEN1KMT2ASIRT5TLR2NPY4R
SCHEMBL12892975 0.92 SIRT5 (0.54) MEN1KMT2ASIRT5TLR2NPY4R
SCHEMBL17350018 0.87 NPY4R (0.53) SIRT5TLR2NPY4RNPY1RNPY2R
SCHEMBL17849796 0.87 NPY4R (0.53) SIRT5TLR2NPY4RNPY1RNPY2R
SCHEMBL13347267 0.84 SIRT5 (0.47) MEN1KMT2ASIRT5TLR2NPY4R
SCHEMBL24918963 0.82 PTPN1 (0.43) SIRT5TLR2NPY4RNPY1RNPY2R
SCHEMBL20799366 0.81 NPY4R (0.49) TLR2NPY4RNPY1RNPY2RNPY5R
SCHEMBL17849843 0.81 NPY4R (0.51) TLR2NPY4RNPY1RNPY2RNPY5R
SCHEMBL14601040 0.81 SIRT5 (0.65) SIRT5TLR2SIRT6SIRT1ALB
SCHEMBL12892988 0.81 SIRT5 (0.55) MEN1KMT2ASIRT5TLR2NPY4R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8450097-B2 Protein-proteophore complexes ASCENDIS PHARMA GMBH (DE) 2013-05-28 US disclosed
US-20110172390-A1 Protein-Proteophore Complexes ASCENDIS PHARMA A/S (DK) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172390-A1 Protein-Proteophore Complexes PSMG3, PSME1, PSMD11 MEN1 3010/4885KMT2A 2932/4885SIRT5 3870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.